105 - In the Era of Shorter Is Better, Does the Data Apply to My Immunocompromised/Transplant Patient? A Critical Review of the Evidence

Friday, October 18, 2024

8:00 AM – 9:00 AM US PT

Location: 403 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Jennifer Cuellar-Rodriguez, MD, FIDSA

Staff Clinician
National Institute of Allergy and infectious Diseases
Bethesda, MD, United States
Jonathan Hand, MD

Section Head, Transplant Infectious Diseases
Ochsner Health
New Orleans, LA, United States

Faculty(s)

David van Duin, MD, PhD

Professor of Medicine
Department of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States
Miranda So, PharmD MPH (she/her/hers)

Manager, Antimicrobial Stewardship Program (SH-UHN ASP)
University Health Network
Mississauga, ON, Canada

Disclosure(s):

Jennifer Cuellar-Rodriguez, MD, FIDSA: No financial relationships to disclose

Jonathan Hand, MD: AstraZeneca: Grant/Research Support; Janssen: Grant/Research Support; Pfizer: Advisor/Consultant, Grant/Research Support; Scynexis: Grant/Research Support

David van Duin, MD, PhD: Merck: Advisor/Consultant (), Grant/Research Support (); Pfizer: Advisor/Consultant (); Qpex: Advisor/Consultant (); Roche: Advisor/Consultant (); Shionogi: Advisor/Consultant (), Grant/Research Support ()

Miranda So, PharmD MPH: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify available evidence for the optimal duration of treatment of gram-negative bacteria in immunocompromised patients (sot, hct, neutropenia);
identify when are shorter/longer courses of antibiotics appropriate in immunocompromised host;
identify gaps in knowledge, and how to proceed at the bedside.

Presentations:

8:00 AM – 8:30 AM US PT

Duration of treatment of Gram-negative bacteremia in immunocompromised patients
Speaker: David van Duin, MD, PhD – University of North Carolina at Chapel Hill
8:30 AM – 9:00 AM US PT

Duration of treatment of infections caused by Pseudomonas aeruginosa and other non-fermenters in transplant or neutropenic patients: an appraisal of current evidence
Speaker: Miranda So, PharmD MPH (she/her/hers) – University Health Network